Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome.
Alzheimer's disease
Down syndrome
basal forebrain
biomarkers
cholinergic
magnetic resonance imaging
neuroimaging
volumetry
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
30
12
2022
received:
03
10
2022
accepted:
04
01
2023
medline:
16
11
2023
pubmed:
7
4
2023
entrez:
6
4
2023
Statut:
ppublish
Résumé
Basal forebrain (BF) degeneration occurs in Down syndrome (DS)-associated Alzheimer's disease (AD). However, the dynamics of BF atrophy with age and disease progression, its impact on cognition, and its relationship with AD biomarkers have not been studied in DS. We included 234 adults with DS (150 asymptomatic, 38 prodromal AD, and 46 AD dementia) and 147 euploid controls. BF volumes were extracted from T-weighted magnetic resonance images using a stereotactic atlas in SPM12. We assessed BF volume changes with age and along the clinical AD continuum and their relationship to cognitive performance, cerebrospinal fluid (CSF) and plasma amyloid/tau/neurodegeneration biomarkers, and hippocampal volume. In DS, BF volumes decreased with age and along the clinical AD continuum and significantly correlated with amyloid, tau, and neurofilament light chain changes in CSF and plasma, hippocampal volume, and cognitive performance. BF atrophy is a potentially valuable neuroimaging biomarker of AD-related cholinergic neurodegeneration in DS.
Sections du résumé
BACKGROUND
Basal forebrain (BF) degeneration occurs in Down syndrome (DS)-associated Alzheimer's disease (AD). However, the dynamics of BF atrophy with age and disease progression, its impact on cognition, and its relationship with AD biomarkers have not been studied in DS.
METHODS
We included 234 adults with DS (150 asymptomatic, 38 prodromal AD, and 46 AD dementia) and 147 euploid controls. BF volumes were extracted from T-weighted magnetic resonance images using a stereotactic atlas in SPM12. We assessed BF volume changes with age and along the clinical AD continuum and their relationship to cognitive performance, cerebrospinal fluid (CSF) and plasma amyloid/tau/neurodegeneration biomarkers, and hippocampal volume.
RESULTS
In DS, BF volumes decreased with age and along the clinical AD continuum and significantly correlated with amyloid, tau, and neurofilament light chain changes in CSF and plasma, hippocampal volume, and cognitive performance.
DISCUSSION
BF atrophy is a potentially valuable neuroimaging biomarker of AD-related cholinergic neurodegeneration in DS.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4817-4827Subventions
Organisme : NIA NIH HHS
ID : R01 AG056480
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG056850
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG056974
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG013566
Pays : United States
Informations de copyright
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol. 1983;214(2):170-197.
Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 1976;99(3):459-496.
Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2(8000):1403.
Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci. 1977;34(2):247-265.
Perry EK, Blessed G, Tomlinson BE, et al. Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. Neurobiol Aging. 1981;2(4):251-256.
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537):1237-1239.
Pearson RC, Sofroniew MV, Cuello AC, et al. Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase. Brain Res. 1983;289(1-2):375-379.
Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol. 1989;105(3):221-232.
Grothe M, Heinsen H, Teipel S. Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiol Aging. 2013;34(4):1210-1220.
Grothe M, Zaborszky L, Atienza M, et al. Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. Cereb Cortex. 2010;20(7):1685-1695.
Grothe MJ, Ewers M, Krause B, Heinsen H, Teipel SJ. Alzheimer's disease neuroimaging initiative. Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement. 2014;10:S344-S353. 5 Suppl.
Schmitz TW, Nathan Spreng R. Alzheimer's disease neuroimaging initiative. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat Commun. 2016;7:13249.
Cantero JL, Atienza M, Lage C, et al. Atrophy of basal forebrain initiates with tau pathology in individuals at risk for Alzheimer's disease. Cereb Cortex. 2020;30(4):2083-2098.
Kerbler GM, Fripp J, Rowe CC, et al. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease. Neuroimage Clin. 2015;7:105-113.
Teipel SJ, Cavedo E, Hampel H, Grothe MJ, Alzheimer's Disease Neuroimaging Initiative. Basal forebrain volume, but not hippocampal volume, is a predictor of global cognitive decline in patients with Alzheimer's disease treated with cholinesterase inhibitors. Front Neurol. 2018;9:642.
Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. Alzheimer's disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol. 2021;20(11):930-942.
Yates CM, Simpson J, Maloney AF, Gordon A, Reid AH. Alzheimer-like cholinergic deficiency in Down syndrome. Lancet. 1980;2(8201):979.
Casanova MF, Walker LC, Whitehouse PJ, Price DL. Abnormalities of the nucleus basalis in Down's syndrome. Ann Neurol. 1985;18(3):310-313.
Mann DM, Yates PO, Marcyniuk B. Some morphometric observations on the cerebral cortex and hippocampus in presenile Alzheimer's disease, senile dementia of Alzheimer type and Down's syndrome in middle age. J Neurol Sci. 1985;69(3):139-159.
Pujol J, Fenoll R, Ribas-Vidal N, et al. A longitudinal study of brain anatomy changes preceding dementia in Down syndrome. Neuroimage Clin. 2018;18:160-166.
Fortea J, Vilaplana E, Carmona-Iragui M, et al. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet. 2020;395(10242):1988-1997.
Alcolea D, Clarimón J, Carmona-Iragui M, et al. The Sant Pau initiative on neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement. 2019;5:597-609.
Kaufman AS, Kaufman NL, KBIT2: Kaufmann Brief Intelligence Test. 3rd Ed. Pearson/PsychCorp; 2004.
Ball SL, Holland AJ, Huppert FA, Treppner P, Watson P, Hon J. The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down's syndrome. J Intellect Disabil Res. 2004;48:611-620. Pt 6.
Esteba-Castillo S, Dalmau-Bueno A, Ribas-Vidal N, Vilà-Alsina M, Novell-Alsina R, García-Alba J. Adaptation and validation of CAMDEX-DS (Cambridge examination for mental disorders of older people with Down's syndrome and others with intellectual disabilities) in Spanish population with intellectual disabilities. Rev Neurol. 2013;57(8):337-346.
Devenny DA, Zimmerli EJ, Kittler P, Krinsky-McHale SJ. Cued recall in early-stage dementia in adults with Down's syndrome. J Intellect Disabil Res. 2002;46:472-483. Pt 6.
Fortea J, Carmona-Iragui M, Benejam B, et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17(10):860-869.
Benejam B, Videla L, Vilaplana E, et al. Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests. Alzheimers Dement. 2020;12(1):e12047.
Videla L, Benejam B, Pegueroles J, et al. Longitudinal clinical and cognitive changes in the Alzheimer´s disease continuum in Down syndrome. JAMA Netw Open. 2022;5(8):e2225573.
Fritz HCJ, Ray N, Dyrba M, Sorg C, Teipel S, Grothe MJ. The corticotopic organization of the human basal forebrain as revealed by regionally selective functional connectivity profiles. Hum Brain Mapp. 2019;40(3):868-878.
Mesulam MM. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. J Comp Neurol. 2013;521(18):4124-4144.
Mesulam MM, Mufson EJ, Wainer BH, Levey AI. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience. 1983;10(4):1185-1201.
Voevodskaya O, Simmons A, Nordenskjöld R, et al. The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease. Front Aging Neurosci. 2014;6:264.
Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433.
Mattsson N, Andreasson U, Persson S, et al. CSF biomarker variability in the Alzheimer's association quality control program. Alzheimers Dement. 2013;9(3):251-261.
Alcolea D, Pegueroles J, Muñoz L, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Ann Clin Transl Neurol. 2019;6(9):1815-1824.
Iulita MF, Garzón Chavez D, Klitgaard Christensen M, et al. Association of Alzheimer disease with life expectancy in people with down syndrome. JAMA Netw Open. 2022;5(5):e2212910.
Fortea J, Vilaplana E, Alcolea D, et al. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann Neurol. 2014;76(2):223-230.
Wong TP, Debeir T, Duff K, Cuello AC. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci. 1999;19(7):2706-2716.
Boncristiano S, Calhoun ME, Kelly PH, et al. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci. 2002;22(8):3234-3243.
Teipel SJ, Fritz HC, Grothe MJ. Alzheimer's disease neuroimaging initiative. Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease. Neurology. 2020;95(10):e1301-e1311.
Pentz R, Iulita MF, Ducatenzeiler A, Bennett DA, Cuello AC. The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. Mol Psychiatry. 2021;26(10):6023-6037.
Pentz R, Iulita MF, Ducatenzeiler A, et al. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: a paired CSF and plasma study. Alzheimers Dement. 2021;17(4):605-617.
Li W, van Tol MJ, Li M, et al. Regional specificity of sex effects on subcortical volumes across the lifespan in healthy aging. Hum Brain Mapp. 2014;35(1):238-247.
Salehi A, Gonzalez Martinez V, Swaab DF. A sex difference and no effect of ApoE type on the amount of cytoskeletal alterations in the nucleus basalis of Meynert in Alzheimer's disease. Neurobiol Aging. 1998;19(6):505-510.
Liu S, Seidlitz J, Blumenthal JD, Clasen LS, Raznahan A. Integrative structural, functional, and transcriptomic analyses of sex-biased brain organization in humans. Proc Natl Acad Sci U S A. 2020;117(31):18788-18798.
Bejanin A, Iulita MF, Vilaplana E, et al. Association of apolipoprotein E ɛ4 allele with clinical and multimodal biomarker changes of Alzheimer disease in adults with down syndrome. JAMA Neurol. 2021;78(8):937-947. Published online July 6.
Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol. 2010;8(1):69-80.
Feldman HH, Pirttila T, Dartigues JF, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry. 2009;24(5):479-488.
Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc. 2003;51(6):737-744.
Anaclet C, Pedersen NP, Ferrari LL, et al. Basal forebrain control of wakefulness and cortical rhythms. Nat Commun. 2015;6:8744.